PHYHIPL activators encompass a diverse range of chemical compounds that exert their effects through various biochemical mechanisms to enhance the protein's functional activity. For instance, certain small molecules directly stimulate enzymes such as adenylyl cyclase, leading to an increase in intracellular cAMP levels, which are known to influence diverse cellular pathways, and could thereby enhance the activity of PHYHIPL. Other activators include inhibitors of phosphodiesterases, which prevent the degradation of cAMP and cGMP, again contributing to conditions that may favor the activation of PHYHIPL. Additionally, the use of compounds that mimic the cellular energy state, like AMP analogs, activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis, which in turn can initiate a cascade of signaling events that promote PHYHIPL activation. Moreover, the modulation of cell cycle progression through the inhibition of cyclin-dependent kinases may create a cellular environment conducive to the upregulation of PHYHIPL.
The regulation of PHYHIPL activity can also be influenced by compounds that affect gene expression through epigenetic mechanisms. Histone deacetylase (HDAC) inhibitors, for example, lead to increased acetylation of histones and may cause upregulation of PHYHIPL, altering its expression levels and potentially its activity. Cellular stress responses such as autophagy, induced by certain polyamines, provide another route through which the activity of PHYHIPL could be indirectly increased. This is due to the autophagic process potentially clearing cellular debris and misfolded proteins, thus potentially affecting the function of PHYHIPL. Additionally, the administration of NAD+ precursors and related sirtuin activators may also influence the activity of PHYHIPL through post-translational modifications such as deacetylation. Furthermore, modulation of signaling pathways by inhibitors of glycogen synthase kinase-3β (GSK-3β) or phosphoinositide 3-kinases (PI3K) can create a milieu that indirectly supports the activation of PHYHIPL, thereby influencing its role within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Directly stimulates adenylyl cyclase, increasing cAMP levels which can enhance the activity of PHYHIPL. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective phosphodiesterase inhibitor, elevates cAMP and cGMP which may indirectly activate PHYHIPL. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AMP analog that activates AMPK, which can lead to downstream events promoting PHYHIPL activation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Inhibits cyclin-dependent kinases, altering cell cycle progression and possibly upregulating PHYHIPL. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C, which can modulate pathways linked to PHYHIPL activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
HDAC inhibitor leading to hyperacetylation of histones, possibly causing increased expression of PHYHIPL. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
HDAC inhibitor that can result in enhanced acetylation and potential upregulation of PHYHIPL. | ||||||
Spermidine | 124-20-9 | sc-215900 sc-215900B sc-215900A | 1 g 25 g 5 g | $57.00 $607.00 $176.00 | ||
Induces autophagy which could lead to cellular conditions favoring PHYHIPL activity. | ||||||
β-Nicotinamide mononucleotide | 1094-61-7 | sc-212376 sc-212376A sc-212376B sc-212376C sc-212376D | 25 mg 100 mg 1 g 2 g 5 g | $110.00 $150.00 $220.00 $300.00 $600.00 | 4 | |
NAD+ precursor, enhancing sirtuin activity which may indirectly activate PHYHIPL through deacetylation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Sirtuin activator, can enhance deacetylation processes potentially linked to PHYHIPL regulation. | ||||||